Porta C - Search Results

1

Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma.

Massari F, Ciccarese C, Bria E, Porta C, La Russa F, Knuutila S, Artibani W, Porcaro AB, Bimbatti D, Modena A, Sava T, Tortora G, Cheng L, Eccher A, Cima L, Pedron S, Ghimenton C, Martignoni G, Brunelli M. Massari F, et al. Among authors: porta c. Appl Immunohistochem Mol Morphol. 2017 Jan;25(1):39-43. doi: 10.1097/PAI.0000000000000257. Appl Immunohistochem Mol Morphol. 2017. PMID: 26509904

2

Sigmoid colon metastasis from sarcomatoid renal cell carcinoma.

Invernizzi R, Bencardino K, Porta C, Vercelli A, Viglio A, Manzoni M, Sagrada P, Danova M. Invernizzi R, et al. Among authors: porta c. Tumori. 2006 May-Jun;92(3):246-8. doi: 10.1177/030089160609200312. Tumori. 2006. PMID: 16869245

3

Tolerability of first-line therapy for metastatic renal cell carcinoma.

Porta C, Szczylik C. Porta C, et al. Cancer Treat Rev. 2009 May;35(3):297-307. doi: 10.1016/j.ctrv.2008.12.003. Epub 2009 Feb 26. Cancer Treat Rev. 2009. PMID: 19249157 Review.

4

Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis.

Ferraris E, Di Cesare P, Lasagna A, Paglino C, Imarisio I, Porta C. Ferraris E, et al. Among authors: porta c. Tumori. 2009 Jul-Aug;95(4):542-4. doi: 10.1177/030089160909500425. Tumori. 2009. PMID: 19856673

5

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, Creel P, Dickow B, Fischer P, Gornell SS, Meloni F, Motzer RJ. Porta C, et al. Eur J Cancer. 2011 Jun;47(9):1287-98. doi: 10.1016/j.ejca.2011.02.014. Epub 2011 Apr 8. Eur J Cancer. 2011. PMID: 21481584 Review.

6

The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.

Imarisio I, Paglino C, Ganini C, Magnani L, Caccialanza R, Porta C. Imarisio I, et al. Among authors: porta c. Future Oncol. 2012 Aug;8(8):1051-7. doi: 10.2217/fon.12.74. Future Oncol. 2012. PMID: 22894676

7

Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science.

Porta C, Sabbatini R, Procopio G, Paglino C, Galligioni E, Ortega C. Porta C, et al. Expert Rev Anticancer Ther. 2012 Dec;12(12):1571-7. doi: 10.1586/era.12.81. Epub 2012 Nov 26. Expert Rev Anticancer Ther. 2012. PMID: 23181412 Review.

8

Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.

Paglino C, Imarisio I, Ganini C, Morbini P, Vercelli A, Bregant C, Porta C. Paglino C, et al. Among authors: porta c. Future Oncol. 2012 Dec;8(12):1605-12. doi: 10.2217/fon.12.145. Future Oncol. 2012. PMID: 23231522 Clinical Trial.

9

Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents.

Massari F, Bria E, Maines F, Milella M, Giannarelli D, Cognetti F, Pappagallo G, Tortora G, Porta C. Massari F, et al. Among authors: porta c. Clin Genitourin Cancer. 2013 Dec;11(4):471-6. doi: 10.1016/j.clgc.2013.04.018. Epub 2013 Jun 28. Clin Genitourin Cancer. 2013. PMID: 23816527

10

Considerations for the design of future clinical trials in metastatic renal cell carcinoma.

Escudier B, Heng DY, Smyth-Medina A, Porta C. Escudier B, et al. Among authors: porta c. Clin Genitourin Cancer. 2014 Feb;12(1):1-12. doi: 10.1016/j.clgc.2013.07.004. Epub 2013 Nov 9. Clin Genitourin Cancer. 2014. PMID: 24220221 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

986 results

Search Page

Filters